Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?

Size: px
Start display at page:

Download "Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?"

Transcription

1 Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be

2 71-year-old man presents with: Clinical Case symptoms of increasing abdominal and back pain anorexia and unitential weight loss of 3 kg in the past two months newly diagnosed diabetes mellitus Comorbidities: ECOG PS: 1 right femoral vein thrombosis and distal pulmonary embolism 10 months ago status post PTCA due to myocardial infarction 2 years ago stage III colon cancer 7 years ago (left hemicolectomy and adjuvant FOLFOX; still feels numbness in his feet) BMI 23 kg/m 2 (weight 70 kg; height 1.75) Patient wants treatment

3 Clinical Case, Cont. Laboratory: Parameter Value Reference Range Hemoglobin (g/l) ALT (U/L) 90 <45 AST (U/L) 68 <35 ALP (U/L) <115 Bilirubin (μmol/l) 15 <17 Albumin (g/l) Creatinine (μmol/l) CA 19-9 (ku/l) 2765 <35 CEA (μg/l) 23 <5

4 CT Scan CT-guided biopsy of the liver: Poorly differentiated adenocarcinoma

5 Treatment of Metastatic Pancreatic Cancer is Palliative Benefits Prolong survival Improve clinical symptoms Improve qualiy of life Toxicity

6 Factors That May Impact Treatment Selection in Metastatic Pancreatic Cancer Efficacy Safety Histopathology Tumor characteristics Patient characteristics Previous treatment Patient preference Goals of therapy Biomarkers

7 Performance Status Is Important in Treatment Decision Making for Advanced Pancreatic Cancer Meta-analysis of randomized trials confirms that performance status is an important factor in determining who is more likely to benefit from combination chemotherapy Performance Status Benefit From Combination Therapy? ECOG PS 0-1/Karnofsky PS 90% to 100% Yes (HR: 0.76; P<.0001) ECOG PS 2/Karnofsky PS 60% to 80% No (HR: 1.08; P =.40) Heinemann V, et al. BMC Cancer. 2008;8:82.

8 Which First-Line Therapy? FOLFIRINOX (? modified FOLFIRINOX) Nab-paclitaxel + gemcitabine Gemcitabine alone Clinical trial (eg, Nal-IRI + 5FU-LV, PEGPH20 + nab-paclitaxel + gemcitabine)

9 Treatment Strategies: ESMO Guideline Ducreux M, et al. Ann Oncol. 2015;26(Supp 5):v56-v68.

10 Gemcitabine Efficacy Gemcitabine 5-FU Clinical benefit (CB), % Median time to achieve CB, weeks Median duration of CB, weeks Median survival, months Median TTP, weeks year survival, % 18 2 Burris HA 3 rd, et al. J Clin Oncol. 1997;15(6):

11 Number of Combination Trials With Gemcitabine Did Not Lead to Clinicaly Meaningful Improvements in Overall Survival Overall Survival Overall Survival Gemcitabine vs: # Patients Control Arm (Gemcitabine Alone) Study Arm (Combined) Gemcitabine + cisplatin months 7.5 months Gemcitabine + oxaliplatin months 9.0 months Gemcitabine + 5-FU months 6.7 months Gemcitabine + capecitabine months 7.1 months Gemcitabine + pemetrexed months 6.2 months Gemcitabine + irinotecan months 6.3 months Gemcitabine + tipifarnib months 6.0 months Gemcitabine + erlotinib months 6.4 months Gemcitabine + bevacizumab months 5.8 months Gemcitabine + cetuximab months 6.4 months Gemcitabine + axitinib months 8.5 months

12 FOLFIRINOX: PRODIGE 4 / ACCORD11 Trial Metastatic PCA ECOG PS 0 or 1 <76 years old Overall Survival (Primary Endpoint) R A N D O M I Z E FOLFIRINOX* N = 171 Gemcitabine N = 171 For both arms: CT scans: obtained every 2 months 6 months of chemotherapy recommended FOLFIRINOX Gemcitabine ORR (%) P value <.001 Median PFS (months) HR (95% CI) 0.47 ( ) P value <.001 Median OS (months) HR (95% CI) 0.57 ( ) P value <.001 Conroy T, et al. N Engl J Med. 2011;364(19): PS, performance status; ORR, objective response rate; PFS, progression free survival

13 FOLFIRINOX Delays Quality of Life Deterioration Despite Less Favorable Toxicity Profile Time until definitive deterioration >20 points in EORTC Core Quality of Life questionnaire global health status Gourgou Bourgade S, et al. J Clin Oncol. 2013;31(1):23 29.

14 FOLFIRINOX: Adverse Events (Grade 3/4) Event Hematologic FOLFIRINOX n = 171 Gemcitabine n = 171 P value Neutropenia 45.7% 21.0% <.001 Febrile neutropenia 5.4% 1.2%.03 Thrombocytopenia 9.1% 3.6%.04 Nonhematologic Fatigue 23.6% 17.8% NS Vomiting 14.5% 8.3% NS Diarrhea 12.7% 1.8% <.001 Sensory neuropathy 9.0% 0.0% <.001 Conroy T, et al. N Engl J Med. 2011;364(19):

15 Nab-Paclitaxel + Gemcitabine: MPACT Trial Stage IV No prior treatment for M1 disease KPS 70 Measurable disease Total bilirubin ULN No age limitation N = 861 Nab-Paclitaxel 125 mg/m 2 IV qw 3/4 + Gemcitabine 1000 mg/m 2 IV qw 3/4 1:1, stratified by KPS, region, liver metastasis Gemcitabine 1000 mg/m 2 IV qw 7/ 8 cycle 1 then qw 3/4 Overall Survival 1 (Primary Endpoint) Independent Review nab-paclitaxel + gemcitabine Gemcitabine ORR 2, % 23 7 P value <.001 Median PFS 2, months HR (95% CI) 0.69 ( ) P value < month alive 2, % Median OS 2, Months < HR (95% CI) 0.72 ( ) P value < Goldstein D, et al. J Natl Cancer Inst. 2015;107(2):dju Von Hoff DD, et al. N Engl J Med. 2013;369(18):

16 Nab-Paclitaxel + Gemcitabine: Adverse Events (Grade 3/4) Grade 3/4 AEs Gemcitabine + nab-paclitaxel (n = 421) Gemcitabine (n = 402) Neutropenia 38% 27% Febrile neutropenia 3% 1% Received growth factors 26% 15% Thrombocytopenia 13% 9% Fatigue 17% 7% Peripheral neuropathy 17% 1% Diarrhea 6% 1% Von Hoff DD, et al. N Engl J Med. 2013;369(18):

17 Key Differences in Front-Line Regimen Studies FOLFIRINOX Nab-Pac + Gemcitabine Median age, yrs (range) 61 (25-76) 62 (27-86) 65 years old 75 years old 29% - 41% 10% Performance status ECOG % Karnofsky % <1 Growth factors use, % Efficacy FOLFIRINOX vs Gem Nab-Pac + Gem vs Gem ORR, % 32 vs 9 23 vs 7 Median PFS, mos 6.4 vs vs 3.7 Median OS, mos 11.1 vs vs 6.7 QOL better for Gem? Yes? Conroy T, et al. N Engl J Med. 2011;364(19): Von Hoff DD, et al. N Engl J Med. 2013;369(18):

18 ASCO Guideline: Metastatic Pancreatic Cancer First-Line Treatment FOLFIRINOX ECOG PS 0 to 1, favorable comorbidity profile, patient preference and support system for aggressive medical therapy, and access to chemotherapy port and infusion pump management services Nab-paclitaxel + gemcitabine ECOG PS 0 to 1, relatively favorable comorbidity profile, and patient preference and support system for relatively aggressive medical therapy Gemcitabine ECOG PS 2 or a comorbidity profile that precludes more-aggressive regimens and patient wish to pursue cancer-directed therapy The addition of either capecitabine or erlotinib to gemcitabine may be offered in this setting Best supportive care ECOG PS 3 or poorly controlled comorbid conditions Should be offered cancer-directed therapy only on a case-by-case basis Sohal D, et al. J Clin Oncol. 2016;34(23):

19 Nal-IRI Containing Regimen in Previously Untreated Pancreatic Adenocarcinoma Randomized Phase II Study Part I nal-iri + 5 FU/LV + oxaliplatin dose escalation Primary endpoint: Safety and tolerability Part 2 nal-iri + 5-FU/LV + oxaliplatin N ~ nal-iri + 5-FU/LV Primary endpoint: PFS nab-paclitaxel + gemcitabine Dean A, et al. J Clin Oncol. 2016;34(suppl 4S): Abstract TPS482. National Institutes of Health. Accessed June 29, 2016.

20 First-Line Treatment Options Gemcitabine Gem + Erlotinib FOLFIRINOX Gem + nab-paclitaxel 1997 PFS 3.55 mos OS 5.65 mos OR 8.0% 2007 PFS 3.75 mos OS 6.24 mos OR 8.6% Skin toxicity 2011 PFS 6.4 mos OS 31.6 mos OR 31.6% Neuropathy Febrile neutropenia 2013 PFS 5.5 mos OS 8.5 mos OR 23.0% Neutropenia

Pancreatic Ca Update

Pancreatic Ca Update Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu

More information

LA CHEMIOTERAPIA DI I LINEA

LA CHEMIOTERAPIA DI I LINEA DECIDERE LA CHEMIOTERAPIA ADIUVANTE E DELLA MALATTIA METASTATICA LA CHEMIOTERAPIA DI I LINEA Michele Reni Department of Medical Oncology IRCCS Ospedale San Raffaele Milan, Italy 1930 1940 1950 1960 1970

More information

Overview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013

Overview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

Pancreatic Cancer. Maribel Tirado Gomez, MD Hematology and Medical Oncology

Pancreatic Cancer. Maribel Tirado Gomez, MD Hematology and Medical Oncology Pancreatic Cancer Maribel Tirado Gomez, MD Hematology and Medical Oncology Disclosures I have no actual or potential financial or commercial conflict of interest in relation to this presentation. Consulting

More information

Tough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France

Tough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Tough to treat tumors in elderly Pancreatic cancer: how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Top 5 causes of cancer death / age Cancer Statistics in the USA 2008, CA

More information

Systemic management of pancreatic cancer: Supportive care

Systemic management of pancreatic cancer: Supportive care Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak Institute for Oncology and Radiology of Serbia Dept. Supportive Oncology & Palliative Care Serbia, Belgrade Integrative Oncology

More information

What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015

What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 Eileen M. O Reilly, M.D. Associate Director David M. Rubenstein Center Pancreatic Cancer Research

More information

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California

More information

Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death

More information

Pancreas Cancer Update Systemic Treatments

Pancreas Cancer Update Systemic Treatments Pancreas Cancer Update Systemic Treatments Carlos R Becerra. Baylor University Medical Center Stage Distribution for Pancreas Cancer in the US (24-21) 1 9 8 7 Axis Title 6 5 4 53 3 28 2 1 9 11 Localized

More information

Avances recientes en el cáncer de páncreas avanzado. P. García Alfonso Jefe de Sección Oncología Médica HGU Gregorio Marañón de Madrid

Avances recientes en el cáncer de páncreas avanzado. P. García Alfonso Jefe de Sección Oncología Médica HGU Gregorio Marañón de Madrid Avances recientes en el cáncer de páncreas avanzado P. García Alfonso Jefe de Sección Oncología Médica HGU Gregorio Marañón de Madrid Pancreatic Cancer: Incidence & Mortality Siegel R, et al. CA Cancer

More information

Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD

Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS

More information

Novel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX

Novel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin

More information

Concept to Practice: New Advances in the Treatment of GI Cancers

Concept to Practice: New Advances in the Treatment of GI Cancers Concept to Practice: New Advances in the Treatment of GI Cancers 2016 Community Oncology Alliance Conference Orlando, FL Thomas George, MD, FACP Director, GI Oncology Program Director, Experimental Therapeutics

More information

Pancreatic Ductal Adenocarcinoma. Razvan Popescu Tumor Center Aarau Switzerland

Pancreatic Ductal Adenocarcinoma. Razvan Popescu Tumor Center Aarau Switzerland Pancreatic Ductal Adenocarcinoma Razvan Popescu Tumor Center Aarau Switzerland Median Survival of Patients With Pancreatic Cancer Localized/ Resectable 15-24 months 10% Locally Advanced 6-15 months 30%

More information

Chemotherapy for Advanced Gastric Cancer

Chemotherapy for Advanced Gastric Cancer Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,

More information

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

ASCO 2010 Update. Advanced Non Small Cell Lung Cancer 7/13/2010. Background. Background. ALK fusion protein. ALK-positive NSCLC

ASCO 2010 Update. Advanced Non Small Cell Lung Cancer 7/13/2010. Background. Background. ALK fusion protein. ALK-positive NSCLC The American Society of Clinical Oncology (ASCO) 2010 Annual Meeting, which returned to Chicago this year, held June 4-8. ASCO 2010 Update Advancing quality through innovation Suphat Subongkot, Pharm.D.,BCPS,

More information

Maintenance paradigm in non-squamous NSCLC

Maintenance paradigm in non-squamous NSCLC Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons

More information

Reference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:

Reference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review: Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer

More information

Incorporating biologics in the management of older patients with metastatic colorectal cancer

Incorporating biologics in the management of older patients with metastatic colorectal cancer Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014

More information

Systemic management of pancreatic cancer: Supportive care

Systemic management of pancreatic cancer: Supportive care Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak @bosnjaksupport Institute for Oncology and Radiology of Serbia Serbia, Belgrade Supportive Care in Cancer The prevention & management

More information

Gourgou-Bourgade, et al DOI: /JCO

Gourgou-Bourgade, et al DOI: /JCO Impact of FOLFIRINO compared with gemcitabine on Quality-of-Life in Patients with Metastatic Pancreatic Cancer: results from the PRODIGE 4/ACCORD 11 randomized trial Gourgou-Bourgade, et al DOI: 10.1200/JCO.2012.44.4869

More information

DALLA CAPECITABINA AL TAS 102

DALLA CAPECITABINA AL TAS 102 DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu

More information

Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma

Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma Original Article Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma Werner Scheithauer 1, Gabriela Kornek 1, Gerald Prager 1, Nadja Stranzl 1, Friedrich

More information

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive

More information

Immunoconjugates in Both the Adjuvant and Metastatic Setting

Immunoconjugates in Both the Adjuvant and Metastatic Setting Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014

pan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014 pan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

Cáncer de Páncreas: Optimización del tratamiento sistémico

Cáncer de Páncreas: Optimización del tratamiento sistémico Cáncer de Páncreas: Optimización del tratamiento sistémico Alfredo Carrato Hospital Universitario Ramón y Cajal, Madrid 16 de Mayo de 2015 Pancreatic cancer screening There is a latency period of about

More information

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14): Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,

More information

Edith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes

Edith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously

More information

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy

More information

Opciones terapéuticas de 1ª línea de cáncer de páncreas metastásico. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla, Santander

Opciones terapéuticas de 1ª línea de cáncer de páncreas metastásico. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla, Santander Opciones terapéuticas de 1ª línea de cáncer de páncreas metastásico Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla, Santander Finantial disclosure Consultor: CELGENE Research fundings:

More information

Pancreatic Cancer: Light at the End of the (Very Long) Tunnel

Pancreatic Cancer: Light at the End of the (Very Long) Tunnel Pancreatic Cancer: Light at the End of the (Very Long) Tunnel Daniel Renouf, MD, MPH, FRCPC Medical Oncologist, BC Cancer Agency University of British Columbia Objectives 1. Discuss recent updates in systemic

More information

SIR-Spheres: Des essais cliniques à la pratique courante

SIR-Spheres: Des essais cliniques à la pratique courante SIR-Spheres: Des essais cliniques à la pratique courante Un focus sur le traitement du mcrc en échappement thérapeutique Dr. Michaël Vouche, MD. PhD. Université Libre de Bruxelles Institut Jules Bordet

More information

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern

More information

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug

More information

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts

More information

What is New in Geriatric Oncology: The Medical Oncology Perspective. Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope

What is New in Geriatric Oncology: The Medical Oncology Perspective. Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope What is New in Geriatric Oncology: The Medical Oncology Perspective Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope Cancer Incidence in the U.S. Between 2010 and 2030, cancer incidence

More information

Best Practices and Promising Agents in Pancreatic Cancer. This program is supported by educational grants from Celgene Corporation and Incyte.

Best Practices and Promising Agents in Pancreatic Cancer. This program is supported by educational grants from Celgene Corporation and Incyte. Best Practices and Promising Agents in Pancreatic Cancer This program is supported by educational grants from Celgene Corporation and Incyte. About These Slides Users are encouraged to use these slides

More information

Advances in Chemotherapy of Colorectal Cancer

Advances in Chemotherapy of Colorectal Cancer Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre

More information

Quimioteràpia per l'adenocarcinoma de pàncrees. Com són de bons els resultats? Que esperem en un futur pròxim?

Quimioteràpia per l'adenocarcinoma de pàncrees. Com són de bons els resultats? Que esperem en un futur pròxim? Quimioteràpia per l'adenocarcinoma de pàncrees. Com són de bons els resultats? Que esperem en un futur pròxim? Carles Pericay (Oncologia. Hospital Parc Taulí) Projecting Cancer Deaths to 2030 Lung Rahib

More information

Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto

Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients

More information

Antiemetic protocol for low-moderately emetogenic chemotherapy (see SCNAUSEA)

Antiemetic protocol for low-moderately emetogenic chemotherapy (see SCNAUSEA) BC Cancer Protocol Summary for First Line Treatment of Locally Advanced Metastatic Pancreatic Cancer with Gemcitabine Protocol Code Tumour Group Contact Physician GIPGEMABR Gastrointestinal GI Systemic

More information

ABSTRACT ORIGINAL RESEARCH

ABSTRACT ORIGINAL RESEARCH Adv Ther (2018) 35:1564 1577 https://doi.org/10.1007/s12325-018-0784-z ORIGINAL RESEARCH Comparative Effectiveness of nab-paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Karcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski

Karcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,

More information

CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER

CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain

More information

Novel Cytotoxic Agents. Suresh S. Ramalingam, MD Associate Professor Director, Division of Medical Oncology Emory University Winship Cancer Institute

Novel Cytotoxic Agents. Suresh S. Ramalingam, MD Associate Professor Director, Division of Medical Oncology Emory University Winship Cancer Institute Novel Cytotoxic Agents Suresh S. Ramalingam, MD Associate Professor Director, Division of Medical Oncology Emory University Winship Cancer Institute Disclosures Scientific Advisory Board (Ad hoc) AVEO,

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

Chemotherapy options and outcomes in older adult patients with colorectal cancer

Chemotherapy options and outcomes in older adult patients with colorectal cancer Critical Reviews in Oncology/Hematology 72 (2009) 155 169 Chemotherapy options and outcomes in older adult patients with colorectal cancer Muhammad W. Saif a,, Stuart M. Lichtman b a Yale University School

More information

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere ) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

EGFR inhibitors in NSCLC

EGFR inhibitors in NSCLC Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance

More information

Systemic Cytotoxic Therapy in advanced HCC

Systemic Cytotoxic Therapy in advanced HCC Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy

More information

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of

More information

GI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management?

GI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management? GI Tumor Board Edward Kim George Poultsides Naseem Esteghamat Kenzo Hirose May Cho Alan Venook Arta Monjazeb Margaret Tempero George Fisher Andrew Ko Daniel Chang Thomas Semrad Sisi Haraldsdottir Case

More information

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program

More information

Pancreatic cancer from the past to the future

Pancreatic cancer from the past to the future Pancreatic cancer from the past to the future Darren Sigal, MD Scripps Clinic Pancreas and Bile Duct Cancer Group Division of Hematology/Oncology Scripps Clinic Pancreas and Bile Duct Cancer Group 1 Objectives

More information

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA

Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev

More information

New chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD

New chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic

More information

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal

More information

Pancreatic Cancer: Medical Therapeutic Approaches

Pancreatic Cancer: Medical Therapeutic Approaches Pancreatic Cancer: Medical Therapeutic Approaches Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat Pancreatic cancer: Why so difficult

More information

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center

More information

Tobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1

Tobias Engel Ayer Botrel 1,2*, Luciana Gontijo de Oliveira Clark 1, Luciano Paladini 1 and Otávio Augusto C. Clark 1 Botrel et al. BMC Cancer (2016) 16:677 DOI 10.1186/s12885-016-2734-y RESEARCH ARTICLE Open Access Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated

More information

RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet

RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive

More information

What s New in Colon Cancer? Therapy over the last decade

What s New in Colon Cancer? Therapy over the last decade What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-

More information

MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra

MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression

More information

Sidra Anwar 1, Wei Tan 2, Jinhee Yu 3, Alan Hutson 2, Milind Javle 4, Renuka Iyer 5. Introduction

Sidra Anwar 1, Wei Tan 2, Jinhee Yu 3, Alan Hutson 2, Milind Javle 4, Renuka Iyer 5. Introduction Original Article Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial Sidra Anwar

More information

Κίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών

Κίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary

More information

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients 1 von 5 23.11.2011 10:52 Home Search Study Topics Glossary Full Text View Tabular View No Study Results Posted Related Studies Panitumumab After Resection of Liver Metastases From Colorectal Cancer in

More information

Tumors in the Randomized German AIO study KRK-0306

Tumors in the Randomized German AIO study KRK-0306 FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German

More information

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;

More information

Metronomic chemotherapy for breast cancer

Metronomic chemotherapy for breast cancer Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition

More information

COMETS: COlorectal MEtastatic Two Sequences

COMETS: COlorectal MEtastatic Two Sequences COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed

More information

Comparing the cost effectiveness of FOLFIRINOX, nab paclitaxel plus gemcitabine, gemcitabine and S 1 for the treatment of metastatic pancreatic cancer

Comparing the cost effectiveness of FOLFIRINOX, nab paclitaxel plus gemcitabine, gemcitabine and S 1 for the treatment of metastatic pancreatic cancer MOLECULAR AND CLINICAL ONCOLOGY 7: 125-130, 2017 Comparing the cost effectiveness of FOLFIRINOX, nab paclitaxel plus gemcitabine, gemcitabine and S 1 for the treatment of metastatic pancreatic cancer MACHIKO

More information

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival

More information

Recent advances in the management of metastatic breast cancer in older adults

Recent advances in the management of metastatic breast cancer in older adults Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the

More information

Third Line and Beyond: Management of Refractory Colorectal Cancer

Third Line and Beyond: Management of Refractory Colorectal Cancer Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting

More information

Squamous Cell Carcinoma Standard and Novel Targets.

Squamous Cell Carcinoma Standard and Novel Targets. Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive

More information

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast

More information

Malignant pleural Mesothelioma: A Year In Review

Malignant pleural Mesothelioma: A Year In Review Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second

More information

MEET MARY KISQALI PATIENT PROFILES

MEET MARY KISQALI PATIENT PROFILES KISQALI PATIENT PROFILES MEET MARY Mary was recently diagnosed with HR+/HER2- metastatic breast cancer Review the data from the MONALEESA-2 trial to see how patients like Mary responded The patient profile

More information

Update on Pancreatic Cancer

Update on Pancreatic Cancer Update on Pancreatic Cancer Farshid Dayyani, MD, PhD Associate Clinical Professor, Department of Medicine, UC Irvine School of Medicine February 2 nd, 2018 Overview Current Systemic Treatments Adjuvant

More information

13TH ANNUAL NEW ORLEANS SUMMER CANCER MEETING

13TH ANNUAL NEW ORLEANS SUMMER CANCER MEETING 13TH ANNUAL NEW ORLEANS SUMMER CANCER MEETING First-line FOLFOX plus panitumumab (pan) followed by 5-FU/LV plus pan or single-agent pan as maintenance therapy in patients with RAS wild-type metastatic

More information

Dr Roopinder Gillmore July 2017

Dr Roopinder Gillmore July 2017 Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not

More information

Pancreatic Cancer Where are we?

Pancreatic Cancer Where are we? Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer

More information

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000

More information

Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy

Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical

More information

Trabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract

Trabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,

More information

MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf

MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance

More information

Medicinae Doctoris. One university. Many futures.

Medicinae Doctoris. One university. Many futures. Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015

pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015 pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended

More information

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease, Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000

More information

Immune checkpoint blockade in lung cancer

Immune checkpoint blockade in lung cancer Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data

More information

Chemotherapy of colon cancers

Chemotherapy of colon cancers Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having

More information